L · 0HTC.L · BIOTECHNOLOGY
Cara Therapeutics, Inc. (0HTC.L) intrinsic value and stock valuation
$15.99as of 2026-11-21 · Mkt cap 24.33M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cara Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values 0HTC.L with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from 0HTC.L’s statements →
Cara Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2024, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue | $7.14M | $21M | $41.9M | $23M | $135.1M |
| Operating income | -$-55.78M | -$-121.5M | -$-87.53M | -$-89.08M | $5.38M |
| Net income | -$-70.87M | -$-118.51M | -$-85.47M | -$-88.44M | $8.41M |
| EPSd | -$-46.63M | -$-2.19M | -$-1.59M | -$-1.74M | $175.5K |
| Operating cash flow | -$-60.92M | -$-92.08M | -$-78.73M | -$-60.09M | -$-5.49M |
| Capital expenditure | -$-1.05M | -$-2.38M | -$-40K | -$-40K | -$-350K |
| Free cash flow | -$-61.96M | -$-94.45M | -$-78.77M | -$-60.13M | -$-5.84M |
| Total assets | $43.8M | $125.8M | $182.2M | $247.1M | $271.2M |
| Total debt | $44.5M | $43.2M | $1.92M | $3.67M | $5.28M |
| Net debt | $6.54M | -$-8.61M | -$-62.23M | -$-9.78M | -$-26.41M |
| Total equity | -$-4.59M | $57.1M | $158.8M | $227.5M | $249M |
| Cash and short-term investments | $37.9M | $100.8M | $145.8M | $167M | $180.9M |
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue | $7.14M | $21M | $41.9M | $23M | $135.1M |
| Cost of revenue | $810K | $113.6M | $7.51M | $1.55M | $107.1M |
| Gross profit | $6.33M | -$-92.58M | $34.4M | $21.5M | $28M |
| Research and development expenses | $32.8M | $108.4M | $91.8M | $82.6M | $107.7M |
| Selling, general and administrative expenses | $26.4M | $28.9M | $31.4M | $30.6M | $22.6M |
| Other expenses | $2.96M | -$-108.38M | -$-1.26M | -$-2.57M | -$-107.74M |
| Operating expenses | $62.1M | $28.9M | $121.9M | $110.6M | $22.6M |
| Cost and expenses | $62.9M | $142.5M | $129.4M | $112.1M | $129.7M |
| Interest income | $2.83M | $3.59M | $2.06M | $600K | $2.06M |
| Interest expense | $8.47M | $600K | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $190K | $260K | $1.67M | $1.55M | $1.01M |
| Ebitda | -$-62.6M | -$-121.24M | -$-83.8M | -$-86.89M | $6.4M |
| Operating income | -$-55.78M | -$-121.5M | -$-87.53M | -$-89.08M | $5.38M |
| Total other income/expenses, net | -$-15.48M | $2.98M | $2.06M | $640K | $2.33M |
| Income before tax | -$-71.27M | -$-118.51M | -$-85.47M | -$-88.44M | $7.72M |
| Income tax expense | -$-400K | $0.00 | $0.00 | $0.00 | -$-690K |
| Net income | -$-70.87M | -$-118.51M | -$-85.47M | -$-88.44M | $8.41M |
| Weighted average shares outstanding | $1.52M | $54.1M | $53.7M | $50.7M | $47.4M |
| Weighted average diluted shares outstanding | $1.52M | $54.2M | $53.7M | $50.7M | $47.9M |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $37.9M | $100.8M | $145.8M | $167M | $180.9M |
| Net receivables | $4.5M | $2.77M | $4.45M | $1.15M | $2.06M |
| Inventory | $900K | $2.82M | $2.38M | $2.58M | $0.00 |
| Total current assets | $43.8M | $116.2M | $168.9M | $173.3M | $195.1M |
| Property, plant and equipment, net | $0.00 | $8.19M | $1.98M | $3.6M | $5.12M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $1.5M | $11.4M | $70.2M | $71M |
| Total non-current assets | $0.00 | $9.69M | $13.3M | $73.8M | $76.1M |
| Total assets | $43.8M | $125.8M | $182.2M | $247.1M | $271.2M |
| Accounts payable | $1.43M | $11.6M | $9.6M | $5.62M | $4.89M |
| Short-term debt | $0.00 | $0.00 | $3.84M | $3.51M | $3.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $3.97M | $25.6M | $23.5M | $17.6M | $18.5M |
| Long-term debt | $44.5M | $43.2M | $0.00 | $1.92M | $3.67M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $44.5M | $43.2M | $0.00 | $1.92M | $3.67M |
| Capital lease obligations | $0.00 | $6.09M | $1.92M | $3.67M | $5.28M |
| Total liabilities | $48.4M | $68.8M | $23.5M | $19.5M | $22.2M |
| Common stock | $10K | $50K | $50K | $50K | $50K |
| Retained earnings | -$-755.61M | -$-684.75M | -$-566.23M | -$-480.76M | -$-392.32M |
| Accumulated other comprehensive income (loss) | $0.00 | -$-260K | -$-1.67M | -$-360K | $70K |
| Total equity | -$-4.59M | $57.1M | $158.8M | $227.5M | $249M |
| Total investments | $0.00 | $50.5M | $93M | $223.7M | $220.2M |
| Total debt | $44.5M | $43.2M | $1.92M | $3.67M | $5.28M |
| Net debt | $6.54M | -$-8.61M | -$-62.23M | -$-9.78M | -$-26.41M |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Net income | -$-70.87M | -$-118.51M | -$-85.47M | -$-88.44M | $8.41M |
| Depreciation and amortization | $190K | $260K | $1.67M | $1.55M | $1.01M |
| Stock-based compensation | $0.00 | $13.7M | $17.7M | $20.8M | $14.8M |
| Change in working capital | -$-15.1M | $6.89M | -$-12.92M | $5.26M | -$-7.37M |
| Accounts receivable | $2.02M | $490K | -$-3.3M | $910K | -$-280K |
| Inventory | -$-1.04M | -$-440K | $200K | -$-2.58M | $0.00 |
| Accounts payable | -$-21.44M | $3.27M | $5.68M | -$-1.02M | -$-2.78M |
| Net cash provided by operating activities | -$-60.92M | -$-92.08M | -$-78.73M | -$-60.09M | -$-5.49M |
| Investments in property, plant and equipment | -$-1.05M | -$-2.38M | -$-40K | -$-40K | -$-350K |
| Acquisitions, net | $0.00 | -$-45.84M | -$-128.75M | $70K | $19.9M |
| Net cash used for investing activities | $48.7M | $43.5M | $128.7M | -$-4.75M | -$-20.27M |
| Common stock issued | $0.00 | $1.68M | $310K | $46.6M | $39.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-3.6M | $38.2M | $310K | $46.6M | $39.1M |
| Net change in cash | -$-14.28M | -$-10.47M | $50.7M | -$-18.23M | $13.4M |
| Cash at end of period | $37.9M | $53.7M | $64.2M | $13.5M | $31.7M |
| Operating cash flow | -$-60.92M | -$-92.08M | -$-78.73M | -$-60.09M | -$-5.49M |
| Capital expenditure | -$-1.05M | -$-2.38M | -$-40K | -$-40K | -$-350K |
| Free cash flow | -$-61.96M | -$-94.45M | -$-78.77M | -$-60.13M | -$-5.84M |
Line items
Line items
Line items
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
- CEO
- Christopher A. Posner
- Employees
- 10
- Beta
- 0.41
Explore
Frequently asked questions
What is the intrinsic value of Cara Therapeutics, Inc. (0HTC.L)?
InvestorsCraft does not currently publish an intrinsic value for 0HTC.L. How the IC value is calculated.
Is 0HTC.L undervalued?
InvestorsCraft does not publish an undervaluation signal for 0HTC.L at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.